Bluejay Diagnostics Announces 1-For-50 Reverse Stock Split, Will Open For Trading On The Nasdaq Capital Market On A Post-Split Basis On November 18, 2024
Bluejay Diagnostics Announces 1-For-50 Reverse Stock Split, Will Open For Trading On The Nasdaq Capital Market On A Post-Split Basis On November 18, 2024
Bluejay Diagnostics, Inc. (NASDAQ:BJDX) ("Bluejay" or the "Company"), a medical technology company developing rapid diagnostics on its Symphony platform to improve patient outcomes in critical care settings, today announced that the Company's Board of Directors has approved a reverse stock split of its shares of common stock at a ratio of 1-for-50 (the "Reverse Stock Split"). The Reverse Stock Split will become effective at 12:01 a.m. Eastern Time on November 18, 2024, and the Company's common stock will open for trading on The Nasdaq Capital Market on a post-split basis on November 18, 2024 under the Company's existing trading symbol, "BJDX." At such time, the Company's common stock will also commence trading with a new CUSIP number, 095633509.
蓝鸟诊断公司（纳斯达克：BJDX）（"蓝鸟"或"公司"）是一家医疗科技公司，正在其交响平台上开发快速诊断，以改善危重护理环境中的患者结果。今天，公司董事会批准了每50股普通股进行1股的反向股票拆分（"反向股票拆分"）。反向股票拆分将在2024年11月18日东部时间凌晨12:01生效，公司的普通股将于2024年11月18日在纳斯达克资本市场按拆分后基础进行交易，交易代码为公司现有的标的"BJDX"。届时，公司的普通股还将以新的CUSIP号码095633509开始交易。
